当前位置:首页 - 行情中心 - 东宝生物(300239) - 财务分析 - 现金流量表

东宝生物

(300239)

  

流通市值:33.97亿  总市值:34.19亿
流通股本:5.90亿   总股本:5.94亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金489,226,887.66342,473,382.7131,526,570.42594,615,415.78
  收到的税费返还3,132,961.813,132,961.8181,063.2311,522,722.37
  收到其他与经营活动有关的现金13,254,958.023,209,237.61,147,946.4123,100,671.14
  经营活动现金流入小计505,614,807.49348,815,582.11132,755,580.06629,238,809.29
  购买商品、接受劳务支付的现金277,542,636.41180,860,276.63117,980,427.27326,493,813.48
  支付给职工以及为职工支付的现金120,249,35380,142,356.8940,146,708.73157,723,585.69
  支付的各项税费34,066,074.3929,073,959.339,161,975.0551,165,757.16
  支付其他与经营活动有关的现金12,339,049.978,446,484.612,999,452.2624,724,534.85
  经营活动现金流出小计444,197,113.77298,523,077.46170,288,563.31560,107,691.18
  经营活动产生的现金流量净额61,417,693.7250,292,504.65-37,532,983.2569,131,118.11
二、投资活动产生的现金流量:
  收回投资收到的现金---1
  处置固定资产、无形资产和其他长期资产收回的现金净额118,103.6791,55532,00034,077,200
  收到的其他与投资活动有关的现金2,909,427,989.541,951,938,996.77941,540,747.682,295,037,577.88
  投资活动现金流入小计2,909,546,093.211,952,030,551.77941,572,747.682,329,114,778.88
  购建固定资产、无形资产和其他长期资产支付的现金46,923,643.0628,827,962.099,457,782.5377,166,502.58
  投资支付的现金---232,000,000
  支付其他与投资活动有关的现金2,905,000,0001,949,000,000940,000,0002,286,000,000
  投资活动现金流出小计2,951,923,643.061,977,827,962.09949,457,782.532,595,166,502.58
  投资活动产生的现金流量净额-42,377,549.85-25,797,410.32-7,885,034.85-266,051,723.7
三、筹资活动产生的现金流量:
  取得借款收到的现金54,400,00054,400,00040,000,0003,000,000
  收到其他与筹资活动有关的现金113,104.02113,104.02-2,389,603.7
  筹资活动现金流入小计54,513,104.0254,513,104.0240,000,0005,389,603.7
  偿还债务支付的现金49,326,70025,686,700-8,000,000
  分配股利、利润或偿付利息支付的现金17,963,157.7915,415,096.64358,713.1915,808,830.21
  支付其他与筹资活动有关的现金56,114,846.3656,114,846.3644,450,000-
  筹资活动现金流出小计123,404,704.1597,216,64344,808,713.1923,808,830.21
  筹资活动产生的现金流量净额-68,891,600.13-42,703,538.98-4,808,713.19-18,419,226.51
四、汇率变动对现金及现金等价物的影响-50,162.06-57,817.13-62,097.883,321.57
五、现金及现金等价物净增加额-49,901,618.32-18,266,261.78-50,288,829.17-215,336,510.53
  加:期初现金及现金等价物余额498,114,881.48498,114,881.48498,114,881.48713,451,392.01
  期末现金及现金等价物余额448,213,263.16479,848,619.7447,826,052.31498,114,881.48
补充资料:
  净利润-36,967,123.15-91,264,128.64
  资产减值准备-2,791,532.1-2,791,007.48
  固定资产和投资性房地产折旧-43,312,666.55-79,015,347.29
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-43,312,666.55-79,015,347.29
  无形资产摊销-3,947,242.74-7,421,477.11
  长期待摊费用摊销-627,993.11-1,385,575.34
  处置固定资产、无形资产和其他长期资产的损失-310,270.68--1,470,574.28
  固定资产报废损失-4,006.27-878,498.01
  财务费用-1,121,054.55-385,286.79
  投资损失-1,566,045.78-3,743,341.08
  递延所得税-1,638,629.23-2,047,061.65
  其中:递延所得税资产减少--1,277,685.07-631,099.1
    递延所得税负债增加-2,916,314.3-1,415,962.55
  存货的减少--40,271,039.06--72,335,773.88
  经营性应收项目的减少-99,887,085.84--11,726,548.76
  经营性应付项目的增加--100,528,958.26--37,617,231.3
  其他--1,081,148.03-3,349,522.94
  现金的期末余额-479,848,619.7-498,114,881.48
  减:现金的期初余额-498,114,881.48-713,451,392.01
  现金及现金等价物的净增加额--18,266,261.78--215,336,510.53
公告日期2025-10-292025-08-292025-04-242025-04-24
审计意见(境内)标准无保留意见
TOP↑